TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer
June 27 2022 - 5:45AM
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell
therapy company with a pipeline of novel T cell therapies for
patients suffering from solid tumors, today announced the
appointment of Eric Sullivan as Chief Financial Officer where he
will be responsible for leading all aspects of financial management
and capital market strategy as well as overseeing investor
relations and select business operations.
“We are excited to announce Eric Sullivan is
joining the TCR2 team as Chief Financial Officer,” said Garry
Menzel, Ph.D., President and Chief Executive Officer of
TCR2 Therapeutics. “Eric brings a tremendous breadth of
financial, strategy, operational and leadership experience to the
Company having served in multiple roles at high-growth companies
during his tenure in the biotechnology industry. As we prepare for
several key inflection points from both our clinical programs,
gavo-cel and TC-510, his appointment will further strengthen our
team to meet the challenges ahead and maximize value for all our
constituents during this next phase of transformational
growth.”
Mr. Sullivan brings to TCR2 nearly 20 years of
finance and operations experience in the biotechnology industry
working on financial management, strategic planning, and
fundraising and capital market transactions across the public and
private markets. Prior to joining the Company, he was President,
Chief Financial Officer and Chief Operating Officer at Triplet
Therapeutics where he led finance, business development and
corporate operations. Before that, Mr. Sullivan led finance as
Senior Vice President at Gemini Therapeutics and Oncorus. Earlier
in his career, he held senior financial management positions at
bluebird bio and Merrimack Pharmaceuticals. Mr. Sullivan holds a
B.S. in Accountancy from Bentley University and is a Certified
Public Accountant (C.P.A.).
“With an extraordinary leadership team and
aspirational vision to change the paradigm for the treatment of
solid tumors, TCR2 represents a leading cell therapy company in a
unique position, especially for the many cancer patients that have
limited or no treatment options,” said Mr. Sullivan. “Joining at
this inflection point is an incredible opportunity to add real
value to the Company by supporting its growth trajectory with two
key programs in the clinic and several others in the pipeline.”
About
TCR2
Therapeutics
TCR2 Therapeutics Inc. is a
clinical-stage cell therapy company developing a pipeline of novel
T cell therapies for patients suffering from solid
tumors. The company is focused on the discovery and
development of product candidates against novel and complex targets
utilizing its proprietary T cell receptor (TCR) Fusion
Construct T cells (TRuC®-T cells). The TRuC platform is
designed to specifically recognize and kill cancer cells by
harnessing signaling from the entire TCR, independent of human
leukocyte antigens (HLA). For more information about TCR2, please
visit www.tcr2.com.
Forward-looking
Statements
This press release contains forward-looking
statements and information within the meaning of the Private
Securities Litigation Reform Act of 1995 and other federal
securities laws. The use of words such as "may," "will," "could",
"should," "expects," "intends," "plans," "anticipates," "believes,"
"estimates," "predicts," "projects," "seeks," "endeavor,"
"potential," "continue" or the negative of such words or other
similar expressions can be used to identify forward-looking
statements. These forward-looking statements include, but are not
limited to, express or implied statements regarding the therapeutic
potential of gavo-cel, TC-510 and TCR2’s other product candidates,
expectations regarding future growth and prospects, future clinical
development, partnering and commercialization plans, the
development of the Company’s TRuC-T cells, their potential
characteristics, applications and clinical utility, and the
potential therapeutic applications of the Company’s TRuC-T cell
platform.
The expressed or implied forward-looking
statements included in this press release are only predictions and
are subject to a number of risks, uncertainties and assumptions,
including, without limitation: uncertainties inherent in clinical
studies and in the availability and timing of data from ongoing
clinical studies; whether interim results from a clinical trial
will be predictive of the final results of the trial; whether
results from preclinical studies or earlier clinical studies will
be predictive of the results of future trials; the expected timing
of submissions for regulatory approval or review by governmental
authorities, including review under accelerated approval processes;
orphan drug designation eligibility; regulatory approvals to
conduct trials or to market products; TCR2’s ability to maintain
sufficient manufacturing capabilities to support its research,
development and commercialization efforts, including TCR2’s ability
to secure additional manufacturing facilities; whether TCR2's cash
resources will be sufficient to fund TCR2's foreseeable and
unforeseeable operating expenses and capital expenditure
requirements, the impact of the COVID- 19 pandemic on TCR2’s
ongoing operations; and other risks set forth under the caption
"Risk Factors" in TCR2’s most recent Annual Report on Form 10-K,
most recent Quarterly Report on Form 10-Q and its other filings
with the Securities and Exchange Commission. In light of these
risks, uncertainties and assumptions, the forward-looking events
and circumstances discussed in this press release may not occur and
actual results could differ materially and adversely from those
anticipated or implied in the forward-looking statements. You
should not rely upon forward- looking statements as predictions of
future events. Although TCR2 believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot guarantee that the future results, levels of activity,
performance or events and circumstances reflected in the
forward-looking statements will be achieved or occur.
Moreover, except as required by law, neither
TCR2 nor any other person assumes responsibility for the accuracy
and completeness of the forward-looking statements included in this
press release. Any forward-looking statement included in this press
release speaks only as of the date on which it was made. We
undertake no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise, except as required by law.
Investor and
Media Contact:
Carl Mauch
Senior Director, Investor Relations and Corporate
Communications
(617) 949-5667
carl.mauch@tcr2.com
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jun 2024 to Jul 2024
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jul 2023 to Jul 2024